BORDERI, MARIA
BORDERI, MARIA
Mostra
records
Risultati 1 - 6 di 6 (tempo di esecuzione: 0.004 secondi).
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir
2022 Calza L, Borderi M, Colangeli V, Miani T, Nuti B, Bon I, Lazzarotto T, Viale P
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up
2020 Calza L, Borderi M, Colangeli V, Borioni A, Coladonato S, Granozzi B, Viale P
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy
2020 Calza L, Tamburello M, Borderi M, Colangeli V, Testi D, Amedeo A, Re MC, Bon I
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir
2020 Calza L.; Colangeli V.; Borderi M.; Bon I.; Borioni A.; Volpato F.; Re M.C.; Viale P.
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study.
2019 Calza L, di Pietro G, Colangeli V, Borderi, Zaghi I, Malosso P, Bon I, Re MC, Viale P
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy
2019 Calza L, Borderi M, Granozzi B, Malosso P, Pancaldi L, Bon I, Re MC